MedTrace Logo

Brimonidine Tartrate for Pterygium Surgery

NCT04683159 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2020-12-24

No results posted yet for this study

Summary

Pterygium excision and conjunctival autograft surgery is commonly done to treat pterygiums. Excessive bleeding during the procedure creates a challenging operating field, prolongs surgery time, and prolongs healing.

Brimonidine tartrate has a vasoconstrictive effect, which helps to reduce the amount of blood flow and hyperemia to the eye. Preoperative use of brimonidine has been shown to decrease subconjunctival hemorrhage during procedures such as cataract surgery, laser assisted in situ keratomileusis, strabismus surgery, and intravitreal injections. The focus of this study is to assess the effect of preoperative application of brimonidine tartrate 0.15% (Alphagan) and 0.025% (Lumify) on reducing hemorrhage during pterygium excision and conjunctival autograft surgery.

Conditions

  • Pterygium
  • Subconjunctival Hemorrhage

Interventions

DRUG

Brimonidine Tartrate 0.15% Oph Soln

1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery

DRUG

Brimonidine Tartrate 0.025% Oph Soln

1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery

Sponsors & Collaborators

  • Uptown Eye Specialists

    lead OTHER

Principal Investigators

  • Eric Tam, MD · Uptown Eye Specialists

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2021-07-31
Completion
2021-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04683159 on ClinicalTrials.gov